Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072214 · ClinicalTrials.gov registry record · Phase 1
A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
A Phase 1 study of Macular Degeneration, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01072214 is a Phase 1 study of Macular Degeneration that has completed, run by GlaxoSmithKline. The registered enrollment target is 37 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01072214, a Phase 1 study of Macular Degeneration, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will be administered to healthy adult volunteers over a 14-day period with one additional dose given on the 15th day of the session. Three groups of subjects may receive either active drug or placebo (drops without drug). The first group of subjects will receive a maximum of 1.6mg of pazopanib or placebo. The dose of drug to be given to the next two groups will be determined based on the results of the first group of subjects. The last group of subjects will be of Japanese descent.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG pazopanib
Study Locations (1)
California
- GSK Investigational Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-03-09 |
| Est. Completion | 2010-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072214
The ClinicalTrials.gov registry entry for NCT01072214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01072214 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01072214 about?
NCT01072214 is a clinical study titled "A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers". A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will be administered to healthy adult volunteers over a 14-day period with one additional dose given on the 15th day of...
What is the current status of trial NCT01072214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2010-03-09. Estimated completion is 2010-06-28.
What conditions does trial NCT01072214 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT01072214?
The interventions under investigation include: Placebo (DRUG), pazopanib (DRUG).
Who is sponsoring clinical trial NCT01072214?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01072214 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
Identification and Treatment of Feeder Vessels in Macular Degeneration
COMPLETED · Phase 1
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
COMPLETED · Phase 1
-
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
COMPLETED · Phase 1
-
Cooling Anesthesia for Intravitreal Injection
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.